HUTCHMED (LON:HCM) Hits New 52-Week Low – Time to Sell?

Posted by on Jun 18th, 2026

HUTCHMED (China) Limited (LON:HCM – Get Free Report)’s share price reached a new 52-week low on Thursday . The company traded as low as GBX 154 and last traded at GBX 156.97, with a volume of 6823 shares trading hands. The stock had previously closed at GBX 157.50.

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 7.91, a quick ratio of 2.97 and a current ratio of 4.96. The company has a market cap of £1.35 billion, a PE ratio of 2.96 and a beta of 0.45. The company’s 50 day moving average price is GBX 189.77 and its 200-day moving average price is GBX 204.99.

About HUTCHMED

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).

Read More

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.